ArticleJournal of the American Academy of Dermatology2020
Should biologics for psoriasis be interrupted in the era of COVID-19?
Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 6 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review.American journal of clinical dermatology · 2022Pooled it
- Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies.The Journal of allergy and clinical immunology · 2021Pooled it
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.Annals of the rheumatic diseases · 2021Guideline
- Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic.Dermatologic therapy · 2020Pooled it
- Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Guideline
- Identification of angiogenesis-related genes and molecular subtypes for psoriasis based on random forest algorithm.Clinical and experimental immunology · 2024Article
- Vaccination Rates in Patients with Chronic Inflammatory Skin Diseases and Immunomodulatory Systemic Therapies-Vaccinations against SARS-CoV-2, Influenza Virus or Varicella Zoster Virus.Life (Basel, Switzerland) · 2024Article
- Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest.Journal of clinical medicine · 2024Article
- A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks.Dermatology reports · 2024Article
- Article
- Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries.Psoriasis (Auckland, N.Z.) · 2024Article
- Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients.Life (Basel, Switzerland) · 2023Article
- Complexity of the Immune Response Elicited by Different COVID-19 Vaccines, in the Light of Natural Autoantibodies and Immunomodulatory Therapies.International journal of molecular sciences · 2023Article
- Review
- Psoriasis comorbidity management in the COVID era: a pressing challenge.Frontiers in microbiology · 2023Review
- COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data.Journal of managed care & specialty pharmacy · 2022Article
- Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?International journal of molecular sciences · 2022Review
- Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide.Archives of dermatological research · 2022Article
- Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.Journal of clinical medicine · 2022Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.